AbbVie, a BigPharma company, is acquiring the IP for a single psychedelic drug from Gilgamesh, a drug dev co, for $1.2 billion
the drug is not even approved yet. it's still in early clinical trials
what does that all mean? for one thing, it means that psychedelic drug IP tokens are severely undervalued
these are some of the most valuable drugs in the history of humanity
mega re-rate soon for
$LSD and
$PSILO
and for the ai system proposing novel psychedelic drugs on the weekly:
$BeeARD
get on board or get left behind